Wojtecki, Lars
Cont, Celine
Stute, Natalie
Galli, Anastasia
Schulte, Christina
Trenado, Carlos
Article History
Received: 27 October 2023
Accepted: 29 July 2024
First Online: 27 August 2024
Declarations
:
: This EEG study was conducted in accordance with the Ethics Committee of the regional Medical Chamber (Ärztekammer Nordrhein, Nr. 2021137). Patients signed a written consent for participation. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
: The authors have the right to publish the data expressed in the manuscript.
: LW has previously received funding grants and institutional support from the German Research Foundation, Hilde-Ulrichs-Stiftung für Parkinsonforschung, and the ParkinsonFonds Germany, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum. Lars Wojtecki owns stock in company BioNTech SE. Lars Wojtecki is a consultant to the following companies: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed, Vertanical.The other authors have no competing interests to declare.